Dynamics of reactive oxygen metabolites and biological antioxidant potential in the acute stage of Kawasaki disease

Circulation Journal

Volumn 75, Issue 10, 2011, Pages 2453-2459

  Yahata, Tomoyo ^a   Suzuki, Chinatsu ^a   Hamaoka, Akiko ^a   Fujii, Maiko ^a   Hamaoka, Kenji ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Biological antioxidant potential; Intravenous immunoglobulin; Kawasaki disease; Reactive oxygen metabolites; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; PREDNISOLONE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ANTIOXIDANT POTENTIAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; INFANT; MALE; METABOLITE; MOLECULAR DYNAMICS; MUCOCUTANEOUS LYMPH NODE SYNDROME; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE;

ACUTE DISEASE; ANTIOXIDANTS; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; OXIDATION-REDUCTION; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME; VASCULITIS;

EID: 80053064061     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0605     Document Type: Article

References (41)

1. Kawasaki T. Kawasaki disease. Proc Jpn Acad Ser B 2006; 82: 59-71.
2. Landing BH, Larson EJ. Pathological features of Kawasaki disease (mucocutaneous lymph node syndrome). Am J Cardiovasc Pathol 1987; 1: 218-229.
3. Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease: With particular emphasis on arterial lesions. Acta Pathol Jpn 1991; 41: 785-797.
4. Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions. Jpn Circ J 1979; 43: 741-748.
5. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004; 364: 533-544.
6. Sies H. Oxidative stress: Inductor remarks. In: Sies H, editor. Oxidative stress. London: Academic Press, 1985; 1-8.
7. Sies H. What is oxidative stress? In: Kency JF Jr, editor. Oxidative stress and vascular disease. Boston: Kluwer Academic Publishers, 2000; 1-8.
8. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411-418.
9. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213-220.
10. Takahashi K, Oharaseki T, Naoe S, Wakayama M, Yokouchi Y. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005; 47: 305-310.
11. Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immuneγ-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 2001; 21: 193-199.
12. Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K. Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-α and interleukin 6 in serum. Eur J Pediatr 1992; 151: 44-47.
13. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr 1992; 21: 924-926.
14. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon gamma in Kawasaki disease involved coronary artery lesions. Clin Immunol Immunopathol 1990; 56: 29-36.
15. Maury CPJ, Salo E, Pelkonen P. Circulating interleukin-1 in patients with Kawasaki disease. N Engl J Med 1988; 319: 1670.
16. Niboshi A, Ozawa S, Hamaoka K. Kawasaki disease and atherosclerosis. Nippon Rinsho 2008; 66: 387-392.
17. Takeuchi D, Saji T, Takatsuki S, Fujiwara M. Abnormal tissue Doppler images are associated with elevated plasma brain natriuretic peptide and increased oxidative stress in acute Kawasaki disease. Circ J 2007; 71: 357-362.
18. Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: Markers and mediators of oxidative stress. FASEB J 2004; 18: 1791-1800.
19. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005; 47: 232-234.
20. Report of JSPCCS. Pediatr Cardiol Cardiac Surg 2004; 24: 54-62.
21. Verde V, Fogliano V, Ritieni A, Maiami G, Morisco F, Caporaso N. Use of N, N-dimethylp-phenylene-diamine to evaluate the oxidative status of human plasma. Free Radic Res 2002; 36: 869-873.
22. Cesarone MR, Belcaro G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L, et al. A simple test to monitor oxidative stress. Int Ang 1999; 2: 127-130.
23. Dohi K, Satoh K, Nakamachi T, Yofu S, Hiratsuka K, Nakamura S, et al. Does edaravone (MCI-186) act as an antioxidant and neuroprotector in experimental traumatic brain injury? Antioxid Redox Signal 2007; 8: 281-287.
24. Nagata K, Hasegawa T, Hirokado Y, Kiyama K, Otsuki C. Lifestylerelated diseases and the oxidative stress regulation system. Jpn J Psychosom Med 2008; 48: 177-183.
25. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 2006; 8: 691-728.
26. Buttery LDK, Springall DR, Chester AH, Evans TJ, Standfield N, Parums DV, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77-85.
27. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
28. Phan SH, Gannon DE, Varani J, Ryan US, Ward PA. Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils. Am J Pathol 1989; 134: 1201-1211.
29. Woo CH, You HJ, Cho SH, Eom YW, Chun JS, Yoo YJ, et al. Leukotriene B4 stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. J Biol Chem 2002; 277: 8572-8578.
30. Tsuchiya M, Kagan VE, Freisleben HJ, Manabe M, Packer L. Antioxidant activity of alpha-tocopherol, beta-carotene, and ubiquinol in membranes: Cis-parinaric acid-incorporated liposomes. Methods Enzymol 1994; 234: 371-383.
31. Hatta A, Frei B. Oxidative modification and antioxidant protection of human low density lipoprotein at high and low oxygen partial pressures. J Lipid Res 1995; 36: 2383-2393.
32. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915-7922.
33. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998; 78: 547-581.
34. Alberti A, Bolognini L, Macciantelli D, Caratelli M. The radical cation of N,N-diethyl-para-phenylendiamine: A possible indicator of oxidative stress in biological samples. Res Chem Intermed 2000; 26: 253-267.
35. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109(25 Suppl 1): IV6-IV19.
36. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
37. Halliwell B, Gutteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990; 280: 1-8.
38. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": The FRAP assay. Anal Biochem 1996; 239: 70-76.
39. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gammaglobulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007; 166: 131-137.
40. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008; 153: 117-121.
41. Suzuki A, Miyagawa-Tomita S, Nakazawa M, Yutani C. Remodeling of coronary artery lesions due to Kawasaki disease: Comparison of arteriographic and immunohistochemical findings. Jpn Heart J 2000; 41: 245-256. doi: 10.1253/circj.CJ-10-0605.